You are here

Article Text

Article menu

Download PDFPDF

Invited Speaker Presentation
S43. Dendritic cell vaccination combined with CTLA4 blockade
  1. K Thielemans1 and
  2. B Neyns2
  1. Aff1 grid.8767.e0000 0001 2290 8069Vrije Universiteit BrusselFaculty of Medicine and Pharmacy Brussels Belgium
  2. Aff2 grid.411326.30000 0004 0626 3362University Hospital BrusselsOncology Brussels Belgium

http://dx.doi.org/10.1186/2051-1426-2-S2-I9

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Electroporation of DC with mRNA also allows the loading of these cells with tumor antigens and the functional modification of the cellular vaccine. To this goal, we provide three different molecular adjuvants to immature, monocyte derived DCs through electroporation with mRNA coding for CD40L, CD70 and caTLR4 or so-called TriMix mRNA.

    At our institution, clinical trials in pretreated advanced melanoma patients are being performed. These patients are treated with TriMixDC-MEL, a mixture of TriMix-DC co-electroporated with mRNA encoding a fusion of DC.LAMP and 1 of 4 melanoma associated antigens (gp100, tyrosinase, MAGE-C2 or MAGE-A3).

    Results

    In a pilot clinical trial, 24.106 TriMixDC-MEL cells were administrated solely by the intradermal (ID) route. Subsequently, a phase IB was conducted to investigate the safety of administrating TriMixDC-MEL by the intravenous (IV) and ID-route. ID administration of TriMixDC-MEL was found to be feasible, safe, effectively stimulating CD8+ T-cell responses, but did not result in objective tumor responses. In contrast, the combined ID/IV administration is associated with distinct but manageable side-effects and has seemingly superior clinical activity as compared to DC administered solely ID in patients with pretreated advanced melanoma. We also investigated the safety and activity of TriMixDC-MEL combined with ipilimumab. The best objective tumor response observed in this trial (37 evaluable pts) were 6 CR, 6 PR, 7 SD and 16 PD (disease control rate: 51%). All 6 CR and 3 PR are currently ongoing (respectively after 23, 22, 20, 20, 19, 17, 15, 14, 14 months). This phase II study of TriMixDC-MEL ID/IV in combination with ipi demonstrates anti-melanoma activity in over 50% of the patients with therapy resistant advanced melanoma.

    Conclusion

    Further clinical development of TriMixDC-MEL in combination with immune checkpoint modulators is warranted.

    Furthermore, TriMixDC-MEL is currently under evaluation in a randomized phase II trial in the adjuvant setting following resection of macrometastases.